Octride is used to manage the effects of certain neuroendocrine tumors (NETs) by helping to control the overproduction of specific hormones and chemicals. The medication provides symptomatic relief in several key clinical situations.

Its primary use is for the long-term management of acromegaly, a condition typically caused by a pituitary tumor that results in excess growth hormone. Octride also assists in mitigating the severe symptoms associated with NETs of the gastrointestinal tract and pancreas, such as carcinoid tumors and VIPomas. This includes reducing the frequency and intensity of severe secretory diarrhea and episodes of flushing.

Overall, the medication is intended to support the patient's well-being by addressing the specific, debilitating symptoms of these chronic diseases.

Quick Fact: Relief for Acromegaly Symptoms

Quick Fact: Relief for Carcinoid Syndrome Diarrhea and Flushing

Quick Fact: Relief for VIPoma-Related Watery Diarrhea

Regulatory References

1. NIH MedlinePlus guidance on Octreotide uses

Who Can and Cannot Use Octride? — Official Regulatory Information

Contraindications and Core Eligibility

Octride is strictly contraindicated for any patient with a known hypersensitivity or severe allergic reaction to the drug (octreotide) or any of the formulation's components.

Its use is officially established for adult patients diagnosed with conditions such as acromegaly, or specific neuroendocrine tumors like metastatic carcinoid or VIP-secreting tumors (VIPomas), where it suppresses related symptoms.

Restricted and Special Consideration Groups

Summary of Eligibility Constraints

Official labeling defines who can and cannot use the medicine primarily by ruling out patients with hypersensitivity. For all other populations, eligibility is tied to specific adult disease states, with explicit restrictions requiring careful consideration, dose adjustment, or close monitoring for those with renal or hepatic impairment, and a lack of established safety for the pediatric population.

Octride’s official interaction profile is defined by documented effects on drug metabolism, absorption, and pharmacodynamics. The medication may decrease the metabolic clearance of compounds processed by CYP450 enzymes, requiring caution with drugs mainly metabolized by CYP3A4 that possess a narrow therapeutic index, such as quinidine. Pharmacodynamically, Octreotide has an additive effect on reducing heart rate when combined with bradycardia-inducing drugs like beta-blockers. Furthermore, the drug inhibits the secretion of both insulin and glucagon, which officially necessitates monitoring and potential dose adjustment for co-administered insulin and oral antidiabetic drugs. A pharmacokinetic interaction is observed with cyclosporine, where co-administration results in decreased blood levels due to reduced intestinal absorption. Conversely, Octreotide has been shown to increase the bioavailability of bromocriptine. In specific clinical scenarios, a mandatory administration timing rule applies: short-acting Octreotide must be discontinued at least 24 hours prior to administering Lutetium Lu 177 dotatate injection. Regarding other substances, treatment is associated with the malabsorption of dietary fats and reports of depressed Vitamin B12 levels. Regulatory documentation also notes that patients with liver cirrhosis show a prolonged elimination half-life of Octreotide itself.

How Octreotide Works: Mechanism of Action

Octreotide is a synthetic compound that acts as an agonist (activator) of somatostatin receptors (SSTRs), primarily the SSTR2 subtype, located on the membrane of various secretory cells. This binding initiates an inhibitory G-protein signaling cascade, which leads to a decrease in the intracellular messenger cAMP and modulates ion channel activity.

This cellular mechanism results in the suppression of hormone secretion, including the release of pituitary, pancreatic, and various gastrointestinal peptides. This dampening effect is a direct physiological consequence of the cellular signaling blockade.

Furthermore, Octreotide engages mechanisms that influence the gastrointestinal system by altering fluid transport and motility. The drug's action causes a decrease in the secretion of water and electrolytes into the intestines and a reduction in the speed of gut movement. Additionally, its mechanism extends to activating internal signaling sequences that interfere with the cell's capacity for growth and proliferation in susceptible SSTR-expressing tissues.

How Octreotide is Used

The use of octreotide is strictly governed by its specialized formulation, differentiating between short-term control and chronic maintenance therapy. The medicine is officially administered through three primary routes: subcutaneous (SC) injection, intravenous (IV) infusion/push, and deep intramuscular (IM) injection, with an additional oral delayed-release capsule available for maintenance.

Administration and Dosing Patterns

The immediate-release solution is typically given via SC injection two to four times daily for initial dose titration and acute symptom control, or via IV administration in a hospital setting. The dose must be systematically adjusted from a starting amount, such as 50 mu g three times daily for acromegaly, toward a labeled maintenance range. For long-term therapy, the Long-Acting Release (LAR) Depot is used, administered as a deep IM injection into the gluteal muscle once every four weeks. The LAR Depot must be properly reconstituted from its powder form immediately before use.

Contextual and Population-Specific Rules

Non-negotiable procedural constraints are mandated for proper use. The oral delayed-release capsule must be swallowed whole and taken on an empty stomach—at least one hour before or two hours after a meal. Furthermore, the LAR Depot must never be administered intravenously or subcutaneously. Labels also specify that dose adjustments may be necessary for patients with impaired renal or hepatic function, often recommending a lower starting dose for the LAR Depot in these populations.

Research Evidence / Overview of Studies for Octreotide

This overview describes the research landscape for Octreotide, detailing the types of studies conducted, the specific outcomes measured in those trials, and areas where scientific evidence remains limited or uncertain. This information is derived from official regulatory and peer-reviewed scientific sources.

Evidence for Use in Acromegaly

Research exploring Octreotide in acromegaly, a condition characterized by hormonal imbalance, includes Randomized Controlled Trials (RCTs) and long-term observational cohorts. Researchers primarily measured two critical outcomes: biochemical measurements for the condition, specifically monitoring levels of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) in the blood. A high volume of studies reported measurements showing that these hormone levels were within or close to target ranges in the observed populations. Studies also monitored changes in the size of the pituitary tumor, and reported outcomes often included measurements of tumor volume change.

Evidence for Use in Symptom Measurements for Neuroendocrine Tumors

Research for neuroendocrine tumors (NETs) has explored Octreotide's application in conditions characterized by fluctuating or episodic manifestations, such as severe diarrhea and flushing. The evidence base includes well-controlled RCTs, particularly for symptomatic measurement. Trials monitored symptoms over defined time intervals and also measured related biomarkers in the blood. Trials reported patterns observed where the frequency of both diarrhea and flushing episodes was measured to change among the treated populations. Research has also explored the anti-proliferative effects, with some studies monitoring Time to Tumor Progression (TTP) to evaluate changes in disease growth over the study period.

What is Still Uncertain About Octreotide’s Research Evidence

The existing research contains limitations and uncertainty. Sample sizes were modest in studies for rarer conditions like VIPomas, meaning generalizability is limited and data for certain groups remain insufficient. Findings were mixed regarding the use of Octreotide in preventing chemotherapy-induced diarrhea, leading to varying certainty across studies. Comparative evidence is lacking in some areas, meaning trials have not always directly compared Octreotide against established standards of care under identical conditions. Evidence for long-term outcomes, particularly for very specific, smaller patient subgroups, is not fully established.

Common questions about Octride (FAQ)

Q: Is it possible for the long-acting Octride injection to lose its effect before the next scheduled dose?

Official information indicates the long-acting formulation is designed to provide sustained drug levels in the body over the full four-week dosing period. Stable or steady-state concentrations are usually achieved after the third injection. If concerns arise regarding the duration of the effect, it is important to discuss these observations with a healthcare professional.

Q: What are the possible risks if the long-acting Octride is not administered correctly?

Regulatory documents specify that the long-acting injection is meant only for deep intramuscular (IM) injection, typically into the gluteal muscle. Official warnings state that the drug should never be administered intravenously (IV) or subcutaneously (SC), as the proper route is necessary for the drug to work as intended.

Q: What are the signs of potential gallbladder problems or gallstones related to Octride use?

Adverse events related to the gallbladder, such as the formation of gallstones (cholelithiasis), are common when using this medication. These gallstones can sometimes lead to serious complications like cholecystitis (gallbladder inflammation), cholangitis, or pancreatitis (pancreas inflammation). Regulatory safety notes specify the need for periodic monitoring of gallbladder status, such as by ultrasound.

Q: Is hair loss a commonly reported side effect of Octride therapy?

Yes, regulatory and official product information confirms that hair loss (alopecia) has been reported as a common adverse reaction for Octride. Common side effects are defined as those occurring in at least 1 out of every 100 patients, but fewer than 1 out of every 10 patients.

Q: How long do the initial side effects from the very first injection typically last?

Initial gastrointestinal side effects from the immediate-release form, such as vomiting and abdominal distension (swelling), are sometimes described in clinical reporting as short-lived, often lasting only two to four days. Official product information does not specify the typical duration for all initial side effects.

Q: Are there any known long-term complications associated with years of Octride use?

Studies and official safety notes indicate that the risk of gallbladder abnormalities, including gallstones and sludge, is frequently reported in patients receiving chronic therapy (meaning treatment for a prolonged period). For example, one study of patients treated for 12 months or longer reported gallstones or sludge in over half of the observed patients.

Q: Does Octride cause dizziness or lightheadedness when a patient stands up quickly?

Official information lists dizziness as a common adverse reaction. Additionally, a drop in blood pressure upon standing, known as orthostatic blood pressure decrease, has been reported, though it is considered a less common reaction (occurring in under 1% of patients). This effect is what typically causes lightheadedness when changing positions.

Q: Can Octride decrease the effectiveness of hormonal contraceptives (birth control)?

Official documents advise women of childbearing potential to use adequate contraception while taking Octride. This caution is based on the drug's therapeutic potential to restore fertility, making adequate contraceptive planning necessary.

Q: What considerations exist for older adults starting Octride therapy?

Official pharmacokinetic information for the drug shows that older adults may process the medication differently. Specifically, there is often a decrease in the clearance of the drug, resulting in a significantly increased half-life. Official information states that dose adjustments may be appropriate for this population.

Storage and Disposal Requirements

Official regulatory information for Octreotide defines strict conditions for maintaining drug stability and ensuring safe disposal. The drug must be refrigerated at 2 C to 8 C and protected from light for long-term storage, with explicit instructions not to freeze the product.

Stability and Handling

Disposal

Used needles and syringes must be placed immediately into a designated puncture-resistant sharps container. Any unused medication must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by a healthcare professional.